Atlas Trials

Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

Clinical trial NCT02792088 · COMPLETED

Trial details

NCT number
NCT02792088
Sponsor
IlDong Pharmaceutical Co Ltd
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Hepatitis B
Start date
2015-07-01
Primary completion
2020-02-01
Enrollment
146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.